27 research outputs found
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
Introduction: The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab.Materials and methods: A total of 1381 patients had PD at first-line therapy. 917 patients received lenvatinib as first-line treatment, and 464 patients atezolizumab plus bevacizumab as first-line.Results: 49.6% of PD patients received a second-line therapy without any statistical difference in overall survival (OS) between lenvatinib (20.6 months) and atezolizumab plus bev-acizumab first-line (15.7 months; p = 0.12; hazard ratio [HR] = 0.80). After lenvatinib first-line, there wasn't any statistical difference between second-line therapy subgroups (p = 0.27; sorafenib HR: 1; immunotherapy HR: 0.69; other therapies HR: 0.85). Patients who under-went trans-arterial chemo-embolization (TACE) had a significative longer OS than patients who received sorafenib (24.7 versus 15.8 months, p < 0.01; HR = 0.64). After atezolizumab plus bevacizumab first-line, there was a statistical difference between second-line therapy subgroups (p < 0.01; sorafenib HR: 1; lenvatinib HR: 0.50; cabozantinib HR: 1.29; other therapies HR: 0.54). Patients who received lenvatinib (17.0 months) and those who under-went TACE (15.9 months) had a significative longer OS than patients treated with sorafenib (14.2 months; respectively, p = 0.01; HR = 0.45, and p < 0.05; HR = 0.46).Conclusion: Approximately half of patients receiving first-line lenvatinib or atezolizumab plus bevacizumab access second-line treatment. Our data suggest that in patients progressed to atezolizumab plus bevacizumab, the systemic therapy able to achieve the longest survival is lenvatinib, while in patients progressed to lenvatinib, the systemic therapy able to achieve the longest survival is immunotherapy
J-SAP Study 1-2: Outcomes of Patients With Stable High-Risk Coronary Artery Disease Receiving Medical-Preceding Therapy in Japan : A Comparison With CABG-Preceding Therapy
J-SAP Study 1-2: Outcomes of Patients With Stable High-Risk Coronary Artery Disease Receiving Medical-Preceding Therapy in Japan : A Comparison With CABG-Preceding Therapy
Measurement of Auroral Electric Fields with an Antarctic Sounding Rocket S-310JA-7. 1.DC Electric Field
The results are given on the DC electric field in an active auroral arc and outside the equatorside of it observed with two pairs of orthogonal double probes launched by an Antarctic sounding rocket S-310JA-7 at 191550 UT on March 27,1978 at Syowa Station. The north-south component of the observed electric field was northward (equatorward) in the arc, and southward (poleward) outside the equatorside of the arc with a magnitude of about 20mV/m. The east-west component was mostly westward throughout the rocket flight and smaller (about 5mV/m) in the arc and larger (about 50mV/m) outside the arc. Anticorrelation of the electric field and precipitating particles is evident. An examination of the oppositely inward directed electric fields in the meridional cross section suggests an electrostatic potential configuration responsible for the acceleration of precipitating particles. The observed westward component would have been originated in the large scale earthward plasma convection in the magnetosphere
A case of ruptured duodenal varices treated successfully by endoscopic injection sclerotherapy under radiographic guidance with a mixture of N-butyl-2-cyanoacrylate-lipiodol
Analysis of factors associated with the prognosis of cirrhotic patients who were treated with V2-receptor antagonist for hepatic edema
Simple method for predicting muscle volume loss using geriatric nutritional risk index in hepatocellular carcinoma patients
Outcomes of Patients With Stable Low-Risk Coronary Artery Disease Receiving Medical- and PCI-Preceding Therapies in Japan
Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment
Background/Aim: The SURF trial showed that surgical resection (SR) and percutaneous ultrasonographic guided radiofrequency ablation (RFA) had equal therapeutic effects for small hepatocellular carcinoma (HCC). However, consensus regarding which treatment is appropriate for initial recurrent early-stage HCC remains lacking. This study aimed to elucidate therapeutic efficacy differences between SR and RFA for initial recurrent early-stage HCC. Materials/Methods: From 2000 to 2021, 371 patients with recurrent early-stage HCC (≤3 cm, ≤3 nodules) after undergoing initial curative treatment with SR or RFA were enrolled (median age 72 years; males 269; Child–Pugh A:B, n = 328:43; SR:RFA, n = 36:335). Recurrence-free survival (RFS) and overall survival (OS) were retrospectively evaluated. Results: Although the median albumin–bilirubin (ALBI) score was better in the SR than the RFA group (−2.90 vs. −2.50, p < 0.01), there were no significant differences between them in regard to RFS (median 28.1 months, 95% CI 23.4–50.0 vs. 22.1 months, 95% CI 19.3–26.2; p = 0.34), OS (78.9 months, 95% CI 49.3—not applicable vs. 71.2 months 95% CI, 61.8–84.7; p = 0.337), or complications (8.3% vs. 9.3%; p = 1.0). In sub-analysis for RFS and OS according to ALBI grade revealed no significant differences between the SR and RFA groups (ALBI 1/2 = 28.2/17.5 vs. 24.0/23.4 months; p = 0.881/0684 and ALBI 1/2 = 78.9/58.9 vs. 115.3/52.6 months, p = 0.651/0.578, respectively). Conclusion: This retrospective study found no significant differences in regard to RFS or OS between patients in the SR and the RFA groups for initial recurrence of early-stage HCC after undergoing curative treatment. These results showing equal therapeutic efficacy of SR and RFA confirm the findings of the SURF trial